{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:19:21Z","timestamp":1793848761585,"version":"4.6.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":7,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Objective. To correlate abuse-related pharmacodynamic measures and pharmacokinetic measures after administering immediate-release\/extended-release and immediate-release oxycodone\/acetaminophen fixed-dose combination analgesics<\/jats:p>\n                  <jats:p>Design. Randomized, double-blind, active- and placebo-controlled, 7-way crossover study<\/jats:p>\n                  <jats:p>Setting. Contract research organization<\/jats:p>\n                  <jats:p>Subjects. Nondependent recreational users of prescription opioids.<\/jats:p>\n                  <jats:p>Methods. Participants received single doses of intact immediate-release\/extended-release and immediate-release oxycodone\/acetaminophen 15\/650 mg, intact immediate-release\/extended-release and immediate-release oxycodone\/acetaminophen 30\/1,300 mg, crushed immediate-release\/extended-release and immediate-release oxycodone\/acetaminophen 30\/1,300 mg, and placebo. Measures of pharmacodynamics (pupillometry, drug liking, drug high, good drug effects) and pharmacokinetics were assessed predose and up to 24 hours postdose, and correlations between pharmacokinetic parameters and pharmacodynamic data were explored.<\/jats:p>\n                  <jats:p>Results. Of 61 participants, 55 completed all 7 treatments. Intact immediate-release\/extended-release oxycodone\/acetaminophen produced 50% lower oxycodone peak plasma concentration (Cmax) than immediate-release oxycodone\/acetaminophen. Median oxycodone time to Cmax (tmax) was significantly longer (P&amp;lt;0.001) for intact immediate-release\/extended-release oxycodone\/acetaminophen than immediate-release oxycodone\/acetaminophen. The pharmacokinetics of crushed immediate-release\/extended-release and immediate-release oxycodone\/acetaminophen (30\/1,300 mg) followed a similar pattern. Crushing did not shorten the median oxycodone tmax for immediate-release\/extended-release oxycodone\/acetaminophen (30\/1,300 mg). Strong correlations were observed between oxycodone Cmax and area under the curve from time 0 to time x peak effects and area under the subjective effect curve from time 0 to time x for all subjective effects (R2=0.711\u20130.997).<\/jats:p>\n                  <jats:p>Conclusion. Immediate-release\/extended-release oxycodone\/acetaminophen produced lower oxycodone Cmax and longer tmax than immediate-release oxycodone\/acetaminophen. Lower oxycodone concentrations, particularly at earlier time points, were strongly correlated with lesser positive subjective drug effects.<\/jats:p>","DOI":"10.1111\/pme.12884","type":"journal-article","created":{"date-parts":[[2015,8,25]],"date-time":"2015-08-25T09:23:33Z","timestamp":1440494613000},"page":"539-550","source":"Crossref","is-referenced-by-count":7,"title":["Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone\/Acetaminophen in Recreational Users of Prescription Drugs"],"prefix":"10.1093","volume":"17","author":[{"given":"Terri L.","family":"Morton","sequence":"first","affiliation":[{"name":"**Department of Clinical Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Devarakonda","sequence":"additional","affiliation":[{"name":"**Department of Clinical Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kostenbader","sequence":"additional","affiliation":[{"name":"\u2020 Contract Medical Monitor, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie","family":"Montgomery","sequence":"additional","affiliation":[{"name":"\u2021 Clinical Trial Manager, Clinical Affairs and Program Management, Mallinckrodt Pharmaceuticals, Hazelwood, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Barrett","sequence":"additional","affiliation":[{"name":"\u2021 Clinical Trial Manager, Clinical Affairs and Program Management, Mallinckrodt Pharmaceuticals, Hazelwood, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Webster","sequence":"additional","affiliation":[{"name":"\u00a7 Scientific Affairs, PRA Health Sciences, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,25]]},"reference":[{"key":"2025112802015019100_pme.12884-B1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00228-005-0920-y","article-title":"The effects of tramadol on static and dynamic pupillometry in healthy subjects\u2013the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status","volume":"61","author":"Fliegert","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"2025112802015019100_pme.12884-B2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2710.2010.01203.x","article-title":"Pupillometry in healthy volunteers as a biomarker of tramadol efficacy","volume":"36","author":"Matouskova","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"2025112802015019100_pme.12884-B3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5055\/jom.2009.0022","article-title":"Relationship between rate of infusion and reinforcing strength of oxycodone in humans","volume":"5","author":"Comer","year":"2009","journal-title":"J Opioid Manage"},{"key":"2025112802015019100_pme.12884-B4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1517\/13543780902751622","article-title":"Opioid formulations in development designed to curtail abuse: Who is the target?","volume":"18","author":"Webster","year":"2009","journal-title":"Expert Opin Invest Drugs"},{"key":"2025112802015019100_pme.12884-B5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1526-4637.2009.00736.x","article-title":"Measuring attractiveness for abuse of prescription opioids","volume":"11","author":"Butler","year":"2010","journal-title":"Pain Med"},{"key":"2025112802015019100_pme.12884-B6","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1176\/appi.ajp.2007.07050252","article-title":"Prescription OxyContin abuse among patients entering addiction treatment","volume":"164","author":"Carise","year":"2007","journal-title":"Am J Psychiatry"},{"key":"2025112802015019100_pme.12884-B7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7517-8-29","article-title":"Abuse risks and routes of administration of different prescription opioid compounds and formulations","volume":"8","author":"Butler","year":"2011","journal-title":"Harm Reduct J"},{"key":"2025112802015019100_pme.12884-B8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1526-4637.2012.01380.x","article-title":"Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone","volume":"13","author":"Webster","year":"2012","journal-title":"Pain Med"},{"key":"2025112802015019100_pme.12884-B9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5055\/jom.2011.0061","article-title":"Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users","volume":"7","author":"Schoedel","year":"2011","journal-title":"J Opioid Manage"},{"key":"2025112802015019100_pme.12884-B10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.mayocp.2012.02.022","article-title":"Strategies to reduce the tampering and subsequent abuse of long-acting opioids: Potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering","volume":"87","author":"Stanos","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"2025112802015019100_pme.12884-B11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drugalcdep.2012.12.028","article-title":"Update on tamper-resistant drug formulations","volume":"130","author":"Romach","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"2025112802015019100_pme.12884-B12","volume-title":"Guidance for Industry Abuse-Deterrent Opioids\u2014Evaluation and Labeling","author":"Center for Drug Evaluation and Research","year":"2013"},{"key":"2025112802015019100_pme.12884-B13","volume-title":"Full Prescribing Information","author":"Xartemis\u2122 XR (oxycodone hydrochloride and acetaminophen extended-release tablets)","year":"2014"},{"key":"2025112802015019100_pme.12884-B14","first-page":"38","article-title":"Single-dose pharmacokinetics of MNK-795, an extended-release oxycodone and acetaminophen combination analgesic: Results from 2 active comparator studies","volume":"6","author":"Devarakonda","year":"2014","journal-title":"J Bioequiv Availab"},{"key":"2025112802015019100_pme.12884-B15","first-page":"53","article-title":"Steady-state pharmacokinetics of MNK-795, an extended-release oxycodone and acetaminophen combination analgesic: Results from 2 active comparator studies","volume":"6","author":"Devarakonda","year":"2014","journal-title":"J Bioequiv Availab"},{"key":"2025112802015019100_pme.12884-B16","article-title":"Evaluation of the tamper-resistant properties of extended-release oxycodone\/acetaminophen tablets","author":"Eisenhauer","journal-title":"Drug Dev Ind Pharm"},{"key":"2025112802015019100_pme.12884-B17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3810\/pgm.2014.07.2780","article-title":"Comparison of subjective effects of extended-release versus immediate-release oxycodone\/acetaminophen tablets: A randomized trial","volume":"126","author":"Morton","year":"2014","journal-title":"Postgrad Med"},{"key":"2025112802015019100_pme.12884-B18","volume-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","author":"Hardman","year":"2001","edition":"10th"},{"key":"2025112802015019100_pme.12884-B19","volume-title":"Full Prescribing Information","author":"OxyContin\u00ae (oxycodone HCl extended release tablets)","year":"2011"},{"key":"2025112802015019100_pme.12884-B20","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0022-3565(24)29229-6","article-title":"Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans","volume":"299","author":"Marsch","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2025112802015019100_pme.12884-B21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0885-3924(96)00300-4","article-title":"A pharmacokinetic\/pharmacodynamic study of controlled-release oxycodone","volume":"13","author":"Benziger","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"2025112802015019100_pme.12884-B22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1399-6576.1997.tb04633.x","article-title":"Pharmacokinetics and pharmacodynamics of controlled-release opioids","volume":"41","author":"Kaiko","year":"1997","journal-title":"Acta Anaesthesiol Scand"},{"key":"2025112802015019100_pme.12884-B23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/JCP.0b013e3181c8f088","article-title":"Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone","volume":"30","author":"Shram","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"2025112802015019100_pme.12884-B24","first-page":"589","article-title":"Toward a systematic approach to opioid rotation","volume":"7","author":"Smith","year":"2014","journal-title":"J Pain Res"},{"key":"2025112802015019100_pme.12884-B25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1185\/030079904125003854","article-title":"Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study","volume":"20","author":"Gabrail","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"2025112802015019100_pme.12884-B26","volume-title":"Full Prescribing Information","author":"OPANA\u00ae ER (oxymorphone hydrochloride)","year":"2013"},{"key":"2025112802015019100_pme.12884-B27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","article-title":"Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment","volume":"14","author":"Butler","year":"2013","journal-title":"J Pain"},{"key":"2025112802015019100_pme.12884-B28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc1204141","article-title":"Effect of abuse-deterrent formulation of OxyContin","volume":"367","author":"Cicero","year":"2012","journal-title":"N Engl J Med"},{"key":"2025112802015019100_pme.12884-B29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5055\/jom.2014.0201","article-title":"Preventing and managing aberrant drug-related behavior in primary care: Systematic review of outcomes evidence","volume":"10","author":"Argoff","year":"2013","journal-title":"J Opioid Manage"},{"key":"2025112802015019100_pme.12884-B30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/00325481.2015.997395","article-title":"Human abuse potential of immediate-release\/extended-release versus immediate-release hydrocodone bitartrate\/acetaminophen: A randomized controlled trial in recreational users of prescription opioids","volume":"127","author":"Devarakonda","year":"2015","journal-title":"Postgrad Med"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpme.12884","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/17\/3\/539\/65586688\/painmedicine_17_3_539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/17\/3\/539\/65586688\/painmedicine_17_3_539.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T07:02:04Z","timestamp":1764313324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/17\/3\/539\/1888297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,25]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,8,25]]},"published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/pme.12884","relation":{},"ISSN":["1526-4637","1526-2375"],"issn-type":[{"value":"1526-4637","type":"electronic"},{"value":"1526-2375","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,3]]},"published":{"date-parts":[[2015,8,25]]}}}